Literature DB >> 22976236

Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease.

R S Desikan1, L K McEvoy, D Holland, W K Thompson, J B Brewer, P S Aisen, O A Andreassen, B T Hyman, R A Sperling, A M Dale.   

Abstract

BACKGROUND AND
PURPOSE: Among cognitively healthy older individuals, the relationship among the 2 hallmark proteins of AD (Aβ and τ APOE ε4) and neurodegeneration is not well-understood. Here, we investigated the relationship between Aβ, p-τ, and APOE ε4 on longitudinal brain atrophy in preclinical AD.
MATERIALS AND METHODS: We examined 107 cognitively healthy older adults who underwent longitudinal MR imaging and baseline lumbar puncture. Within the same linear mixed-effects model, we concurrently investigated main and interactive effects between the APOE ε4 genotype and CSF Aβ(1-42), CSF p-τ and CSF Aβ(1-42), and the APOE ε4 genotype and CSF p-τ on entorhinal cortex atrophy rate. We also examined the relationship of APOE ε4, CSF p-τ, and CSF Aβ(1-42) on the atrophy rate of other AD-vulnerable neuroanatomic regions.
RESULTS: The full model with main and interactive effects demonstrated a significant interaction only between CSF p-τ and CSF Aβ(1-42) on entorhinal cortex atrophy rate, indicating elevated atrophy with time in individuals with increased CSF p-τ and decreased CSF Aβ(1-42). The APOE ε4 genotype was significantly and specifically associated with CSF Aβ(1-42). However, the interaction between the APOE ε4 genotype and either CSF Aβ(1-42) or CSF p-τ on entorhinal cortex atrophy rate was not significant. We found similar results in other AD-vulnerable regions.
CONCLUSIONS: On the basis of our findings and building on prior experimental evidence, we propose a model of the pathogenic cascade underlying preclinical AD in which APOE ε4 primarily influences the pathology of Alzheimer disease via Aβ-related mechanisms, and in turn, Aβ-associated neurodegeneration occurs only in the presence of p-τ.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22976236      PMCID: PMC4041629          DOI: 10.3174/ajnr.A3267

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  31 in total

1.  Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Reisa A Sperling; Paul S Aisen; Laurel A Beckett; David A Bennett; Suzanne Craft; Anne M Fagan; Takeshi Iwatsubo; Clifford R Jack; Jeffrey Kaye; Thomas J Montine; Denise C Park; Eric M Reiman; Christopher C Rowe; Eric Siemers; Yaakov Stern; Kristine Yaffe; Maria C Carrillo; Bill Thies; Marcelle Morrison-Bogorad; Molly V Wagster; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

2.  Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1-42.

Authors:  Jonathan M Schott; Jonathan W Bartlett; Nick C Fox; Josephine Barnes
Journal:  Ann Neurol       Date:  2010-12       Impact factor: 10.422

3.  APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.

Authors:  John C Morris; Catherine M Roe; Chengjie Xiong; Anne M Fagan; Alison M Goate; David M Holtzman; Mark A Mintun
Journal:  Ann Neurol       Date:  2010-01       Impact factor: 10.422

Review 4.  Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease.

Authors:  Lars M Ittner; Jürgen Götz
Journal:  Nat Rev Neurosci       Date:  2010-12-31       Impact factor: 34.870

5.  Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models.

Authors:  Lars M Ittner; Yazi D Ke; Fabien Delerue; Mian Bi; Amadeus Gladbach; Janet van Eersel; Heidrun Wölfing; Billy C Chieng; MacDonald J Christie; Ian A Napier; Anne Eckert; Matthias Staufenbiel; Edna Hardeman; Jürgen Götz
Journal:  Cell       Date:  2010-07-22       Impact factor: 41.582

6.  Nonlinear registration of longitudinal images and measurement of change in regions of interest.

Authors:  Dominic Holland; Anders M Dale
Journal:  Med Image Anal       Date:  2011-02-23       Impact factor: 8.545

Review 7.  Alzheimer's disease: the challenge of the second century.

Authors:  David M Holtzman; John C Morris; Alison M Goate
Journal:  Sci Transl Med       Date:  2011-04-06       Impact factor: 17.956

8.  Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition.

Authors:  Martha Storandt; Mark A Mintun; Denise Head; John C Morris
Journal:  Arch Neurol       Date:  2009-12

9.  Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance.

Authors:  Jungsu Kim; Joseph M Castellano; Hong Jiang; Jacob M Basak; Maia Parsadanian; Vi Pham; Stephanie M Mason; Steven M Paul; David M Holtzman
Journal:  Neuron       Date:  2009-12-10       Impact factor: 17.173

10.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

View more
  9 in total

1.  Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.

Authors:  Stephanie Jb Vos; Chengjie Xiong; Pieter Jelle Visser; Mateusz S Jasielec; Jason Hassenstab; Elizabeth A Grant; Nigel J Cairns; John C Morris; David M Holtzman; Anne M Fagan
Journal:  Lancet Neurol       Date:  2013-09-04       Impact factor: 44.182

2.  Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers.

Authors:  Michael J Properzi; Rachel F Buckley; Jasmeer P Chhatwal; Michael C Donohue; Cristina Lois; Elizabeth C Mormino; Keith A Johnson; Reisa A Sperling; Aaron P Schultz
Journal:  Neuroimage       Date:  2018-11-17       Impact factor: 6.556

3.  The role of clusterin in amyloid-β-associated neurodegeneration.

Authors:  Rahul S Desikan; Wesley K Thompson; Dominic Holland; Christopher P Hess; James B Brewer; Henrik Zetterberg; Kaj Blennow; Ole A Andreassen; Linda K McEvoy; Bradley T Hyman; Anders M Dale
Journal:  JAMA Neurol       Date:  2014-02       Impact factor: 18.302

4.  Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus.

Authors:  R S Desikan; A J Schork; Y Wang; A Witoelar; M Sharma; L K McEvoy; D Holland; J B Brewer; C-H Chen; W K Thompson; D Harold; J Williams; M J Owen; M C O'Donovan; M A Pericak-Vance; R Mayeux; J L Haines; L A Farrer; G D Schellenberg; P Heutink; A B Singleton; A Brice; N W Wood; J Hardy; M Martinez; S H Choi; A DeStefano; M A Ikram; J C Bis; A Smith; A L Fitzpatrick; L Launer; C van Duijn; S Seshadri; I D Ulstein; D Aarsland; T Fladby; S Djurovic; B T Hyman; J Snaedal; H Stefansson; K Stefansson; T Gasser; O A Andreassen; A M Dale
Journal:  Mol Psychiatry       Date:  2015-02-17       Impact factor: 15.992

Review 5.  Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers.

Authors:  Li Shen; Paul M Thompson; Steven G Potkin; Lars Bertram; Lindsay A Farrer; Tatiana M Foroud; Robert C Green; Xiaolan Hu; Matthew J Huentelman; Sungeun Kim; John S K Kauwe; Qingqin Li; Enchi Liu; Fabio Macciardi; Jason H Moore; Leanne Munsie; Kwangsik Nho; Vijay K Ramanan; Shannon L Risacher; David J Stone; Shanker Swaminathan; Arthur W Toga; Michael W Weiner; Andrew J Saykin
Journal:  Brain Imaging Behav       Date:  2014-06       Impact factor: 3.978

Review 6.  Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic Criteria.

Authors:  Daniel Ferreira; Lilisbeth Perestelo-Pérez; Eric Westman; Lars-Olof Wahlund; Antonio Sarría; Pedro Serrano-Aguilar
Journal:  Front Aging Neurosci       Date:  2014-03-24       Impact factor: 5.750

7.  Subtle Alterations in Spatial Memory Induced by Amyloid Peptides Infusion in Rats.

Authors:  Priscila Tavares Macêdo; Antônio C Q Aquino; Ywlliane S R Meurer; Luiz E M Brandão; Clarissa L C Campêlo; Ramon H Lima; Marcos R Costa; Alessandra M Ribeiro; Regina H Silva
Journal:  Front Aging Neurosci       Date:  2018-01-30       Impact factor: 5.750

8.  Apolipoprotein E ɛ4-related effects on cognition are limited to the Alzheimer's disease spectrum.

Authors:  Alberto Fernández; Lucía Vaquero; Ricardo Bajo; Pilar Zuluaga
Journal:  Geroscience       Date:  2021-09-30       Impact factor: 7.713

9.  Heart fatty acid binding protein and Aβ-associated Alzheimer's neurodegeneration.

Authors:  Rahul S Desikan; Wesley K Thompson; Dominic Holland; Christopher P Hess; James B Brewer; Henrik Zetterberg; Kaj Blennow; Ole A Andreassen; Linda K McEvoy; Bradley T Hyman; Anders M Dale
Journal:  Mol Neurodegener       Date:  2013-10-02       Impact factor: 14.195

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.